1351946-91-2

Upstream product

• 4530-20-5 BOC-glycine 
• 250612-31-8 3-(N-(3-(2-(2-(3-((tert-butoxy)-carbonylamino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)-propanoic acid 
• 108466-89-3 N-(tert-butyloxycarbonyl)-8-amino-3,6-dioxaoctanoic acid 
• 1021273-74-4 4-(tert-butoxycarbonyl)cyclohexanecarboxylic acid 
• 1351946-83-2 (S)-3-(5-(1-methylpyrrolidin-2-yl)pyridin-3-yl)propan-1-amine 
• 71606-34-3 (-)-5-Bromonicotine 
• 756525-91-4 3-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid 
• 142929-49-5 <2-<<(1,1-dimethylethoxy)carbonyl>amino>ethoxy>acetic acid 
• 1351946-82-1 (S)-3-(5-(1-methylpyrrolidin-2-yl)pyridin-3-yl)propanenitrile 
• 53292-90-3 trans-4-(tert-butoxycarbonylamino)cyclohexanoic acid 
• 54-11-5 nicotin 

Relevant academic research and scientific papers

CONJUGATES FOR PREVENTION OR TREATMENT OF NICOTINE ADDICTION

PROBLEM TO BE SOLVED: To provide nicotine-derived haptens, nicotine-derived hapten-carrier conjugates, and vaccine compositions containing the conjugates, which are useful for enhancing smoking quit rates or reducing smoking relapse rates in smoking cessa

CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION

The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can